Teeple, A, and E Muser. “Cost Per Responder Analysis of Guselkumab Versus Certolizumab Pegol Using Efficacy Results from Pivotal Clinical Trials in Patients With Moderate to Severe Plaque Psoriasis”. SKIN The Journal of Cutaneous Medicine 2 (December 17, 2018): S80. Accessed January 10, 2025. https://skin.dermsquared.com/skin/article/view/477.